tiprankstipranks
Catalent VAI update addresses Brussels shutdown concerns, says Morgan Stanley
The Fly

Catalent VAI update addresses Brussels shutdown concerns, says Morgan Stanley

Morgan Stanley analyst Tejas Savant noted that Catalent’s Brussels facility is now classified under VAI status, or "voluntary action indicated", on the FDA dashboard, which takes the risk related to a shutdown at Brussels "off the table," in the analyst’s view. This news comes on the heels of a similar VAI status for the Bloomington site, which Savant said is supportive of the company’s efforts to work through quality issues at both locations while "mitigating the risk of manufacturing disruptions." Savant has an Overweight rating and $81 price target on Catalent shares.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CTLT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles